Pharmacological Therapy Used in the Elimination of Helicobacter Pylori Infection: a Review

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Jan 10

PMID 25574087

Citations 10

Authors

Ariolana A Dos Santos

Adriana A Carvalho

Affiliations

Soon will be listed here.

Abstract

The optimal therapy for Helicobacter pylori (H. pylori) infection should combine a high cure rate and a short treatment duration with a favorable side-effect profile and should maintain a low cost. Several strategies have been proposed to increase the H. pylori eradication rate, including the extension of the treatment duration to 14 d, the use of a four-drug regimen (quadruple, sequential, and concomitant treatments), and the use of novel antibiotics, such as levofloxacin. However, triple therapy remains the most widely accepted first-line treatment regimen in Brazil and the United States and throughout Europe. Because this therapy is limited by resistance to clarithromycin, other therapeutic regimens have been investigated worldwide. This review describes the current literature involving studies directly comparing these different therapies and their efficacies.

Citing Articles

Salivary glands - a new site of Helicobacter pylori occurrence.

Rotnagl J, Hlozek J, Holy R, Pavlik E, Kalfert D, Astl J J Appl Biomed. 2024; 22(3):141-148.

PMID: 39434511 DOI: 10.32725/jab.2024.018.

Prevalence of cagA, cagM, vacA and oipA genes in isolates of Helicobacter pylori obtained from hospital patients in Northeast Brazil.

Bezerra T, Xavier K, Luz A, Cavalcanti I, de Brito C, Balbino T Braz J Microbiol. 2024; 55(3):2631-2641.

PMID: 38802685 PMC: 11405591. DOI: 10.1007/s42770-024-01380-4.

GC-MS Profiling, Anti-, and Anti-Inflammatory Activities of Three Apiaceous Fruits' Essential Oils.

Alomar H, Fathallah N, Abdel-Aziz M, Ibrahim T, Elkady W Plants (Basel). 2022; 11(19).

PMID: 36235480 PMC: 9570728. DOI: 10.3390/plants11192617.

Bacteriophages of .

Munoz A, Stepanian J, Trespalacios A, Vale F Front Microbiol. 2020; 11:549084.

PMID: 33281754 PMC: 7688985. DOI: 10.3389/fmicb.2020.549084.

ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats.

Marks S, Kook P, Papich M, Tolbert M, Willard M J Vet Intern Med. 2018; 32(6):1823-1840.

PMID: 30378711 PMC: 6271318. DOI: 10.1111/jvim.15337.

References

Liu K, Hung I, Seto W, Tong T, Hsu A, Lam F . Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut. 2013; 63(9):1410-5. DOI: 10.1136/gutjnl-2013-306120. View

Hsu P, Wu D, Chen W, Tseng H, Yu H, Wang H . Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014; 58(10):5936-42. PMC: 4187978. DOI: 10.1128/AAC.02922-14. View

Malfertheiner P, Megraud F, OMorain C, Bazzoli F, El-Omar E, Graham D . Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2006; 56(6):772-81. PMC: 1954853. DOI: 10.1136/gut.2006.101634. View

Ergul B, Kocak E, Tas A, Filik L, Koklu S . Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study. Clin Res Hepatol Gastroenterol. 2013; 37(5):527-9. DOI: 10.1016/j.clinre.2012.10.014. View

Wolle K, Malfertheiner P . Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol. 2007; 21(2):315-24. DOI: 10.1016/j.bpg.2006.11.001. View

Seyedmajidi S, Mirsattari D, Zojaji H, Zanganeh E, Seyyedmajidi M, Almasi S . Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population. Arab J Gastroenterol. 2013; 14(1):1-5. DOI: 10.1016/j.ajg.2012.12.004. View

Dib Jr J, Alvarez B, Mendez L, Cruz M . Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital. Arab J Gastroenterol. 2013; 14(3):123-5. DOI: 10.1016/j.ajg.2013.09.001. View

Kaya A, Ozturk C, Akcan Y, Behcet M, Karakoc A, Yucel M . Prevalence of Helicobacter pylori in symptomatic patients and detection of clarithromycin resistance using melting curve analysis. Curr Ther Res Clin Exp. 2014; 68(3):151-60. PMC: 3967324. DOI: 10.1016/j.curtheres.2007.06.001. View

Zojaji H, Talaie R, Mirsattari D, Haghazali M, Molaei M, Mohsenian N . The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation. Dig Liver Dis. 2009; 41(9):644-7. DOI: 10.1016/j.dld.2008.09.008. View

10.

Bytzer P, Frederik Dahlerup J, Eriksen J, Jarbol D, Rosenstock S, Wildt S . Diagnosis and treatment of Helicobacter pylori infection. Dan Med Bull. 2011; 58(4):C4271. View

11.

Fock K, Katelaris P, Sugano K, Ang T, Hunt R, Talley N . Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009; 24(10):1587-600. DOI: 10.1111/j.1440-1746.2009.05982.x. View

12.

Tanih N, Dube C, Green E, Mkwetshana N, Clarke A, Ndip L . An African perspective on Helicobacter pylori: prevalence of human infection, drug resistance, and alternative approaches to treatment. Ann Trop Med Parasitol. 2009; 103(3):189-204. DOI: 10.1179/136485909X398311. View

13.

Xu M, Zhang G, Li C . [Efficacy of bismuth-based quadruple therapy as first-line treatment for Helicobacter pylori infection]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2011; 40(3):327-31. DOI: 10.3785/j.issn.1008-9292.2011.03.017. View

14.

Karatapanis S, Georgopoulos S, Papastergiou V, Skorda L, Papantoniou N, Lisgos P . "7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial". Acta Gastroenterol Belg. 2011; 74(3):407-12. View

15.

Bang S, Han D, Eun C, Kim J, Ahn S, Sohn J . [Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease]. Korean J Gastroenterol. 2007; 50(6):356-62. View

16.

Rogha M, Pourmoghaddas Z, Rezaee M, Shirneshan K, Shahi Z . Azithromycin effect on helicobacter pylori eradication: double blind randomized clinical trial. Hepatogastroenterology. 2009; 56(91-92):722-4. View

17.

Tursi A, Picchio M, Elisei W . Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection. J Gastrointestin Liver Dis. 2012; 21(2):133-8. View

18.

Chen L, Chien R, Chang J, Fang K, Chang L . Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study. Int J Clin Pract. 2010; 64(11):1530-1534. DOI: 10.1111/j.1742-1241.2010.02482.x. View

19.

Lins A, Lima R, Magalhaes M . Clarithromycin-resistant Helicobacter pylori in Recife, Brazil, directly identified from gastric biopsies by polymerase chain reaction. Arq Gastroenterol. 2011; 47(4):379-82. DOI: 10.1590/s0004-28032010000400011. View

20.

Agah S, Shazad B, Abbaszadeh B . Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for Helicobacter pylori eradication in dyspepsia. Saudi J Gastroenterol. 2009; 15(4):225-8. PMC: 2981837. DOI: 10.4103/1319-3767.56091. View